Magnisense, diagnostic tests for cardiovascular diseases in Paris

Magnisense, diagnostic tests for cardiovascular diseases in Paris

Magnisense designs, develops and commercializes diagnostic tests for cardiovascular diseases using its proprietary MIAtek® technology and instrument.


Our mission is to bring to the market an emergency diagnostic test for cardio-vascular diseases that can be used, directly by emergency physicians, reanimation specialists, cardiologists and other physicians. The test is designed to help save patients' lives and decrease public health costs associated with these diseases. We aim to become a leader in emergency cardiac diagnosis by commercializing competitive tests that efficiently address healthcare and economic issues.

Magnisense, diagnostic tests for cardiovascular diseases in Paris

Magnisense is a pioneer in developing these emergency diag. tests, thanks to its unique set of proprietary ground-breaking technologies including MIAtek® and MIAplex® using magnetic nanoparticles. Its technologies are protected worldwide by a portfolio of patents granted in Europe, United States and Japan. The Magnisense technology can be used to develop tests for virtually any human or non-human application.

 

Magnisense is a French private diagnostic company founded by the eminent scientist and inventor of the technology, Professor Petr Nikitin, and a group of entrepreneurs led by Jean-Patrick Voisin and Daniel Bernard, to address unmet medical needs in diagnostics.


The company's head office is in Paris, and its R&D lab “Le Campus” is located near Lyon, in Dardilly. Magnisense is a member of two competitive clusters, Medicen in Paris and Lyon biopole.